secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOGEN INC. (BIIB)
CIK:        0000875045
Form:       8-K
Filed at:   2022-10-25T23:59:59+00:00
Accession:  0000875045-22-000028
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biogen Q3 2022 revenue $2,508M; GAAP EPS $7.84; raises full-year guidance
-------------------------------------------------------------------------

- Q3 revenue $2,508M, down 10% YoY; MS revenue $1,621M (-11%), SPINRAZA $431M (-3%), Biosimilars $188M (-7%).
- GAAP diluted EPS $7.84; Non-GAAP diluted EPS $4.77.
- Lecanemab Phase 3 Clarity AD met primary endpoint and all key secondary endpoints in early Alzheimer's.
- Tofersen NDA accepted with priority review; PDUFA date April 25, 2023.
- Company raises full year 2022 financial guidance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875045/000087504522000028/0000875045-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875045/000087504522000028/biib-20221025.htm
  HTML page:      https://secwatch.observer/filing/0000875045-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer